Standard Biotools Inc. has 9 Schedule 13D or 13G filings on record since 2025-11-28. 5 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Casdin Capital, LLC | 23.9% | 88,783,856 | SCHEDULE 13D/A, 2026-06-09 | 2026-06-06 |
| Viking Global Investors LP | 15% | 58,651,170 | SCHEDULE 13D, 2026-06-12 | 2026-06-06 |
| Mak Capital One LLC | 7.3% | 28,813,904 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| MAK Capital Fund LP | 6.7% | 26,172,626 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Long Focus Capital Management, LLC | 6% | 23,500,000 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 2% | 7,911,347 | SCHEDULE 13G/A, 2026-07-30 | 2026-06-30 |
Purpose of Transaction (Item 4)
Casdin Capital, LLC
Item 4 of the Schedule 13D amendment filed on November 28, 2025 is hereby supplemented by the addition of the following: On June 6, 2026, the Issuer, Treeline Biosciences, Inc., a Delaware corporation (the "Company"), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into the Company, with the Company continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "Merger"). Upon the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger ("Effective Time"), each share of capital stock of the Company will be converted into the right to receive a number of Shares in accordance with the Exchange Ratio (as defined in the Merger Agreement). Voting Agreement Also on June 6, 2026, in connection with the Merger Agreement, the Issuer, the Company and Merger Sub entered into a voting agreement (the "Voting Agreement") with Casdin Private Growth Equity Fund II, L.P., Casdin Private Growth Equity Fund, L.P., Casdin Partners Master Fund, L.P. and Eli Casdin (collectively, the "Casdin Parties"). Pursuant to the Voting Agreement, the Casdin Parties have agreed, among other things, …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-06-09; the filing has the rest
Viking Global Investors LP
The response to Item 3 of this Schedule 13D is incorporated by reference herein. On June 6, 2026, the Issuer, Treeline Biosciences, Inc., a Delaware corporation ("Treeline"), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Treeline, with Treeline continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "Merger"). Upon the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger ("Effective Time"), each share of capital stock of Treeline will be converted into the right to receive a number of shares of Common Stock in accordance with the Exchange Ratio (as defined in the Merger Agreement). Also on June 6, 2026, in connection with the Merger Agreement, the Issuer, Treeline and Merger Sub entered into a voting agreement (the "Voting Agreement") with VGOP and VGOD. Pursuant to the Voting Agreement, VGOP and VGOD have agreed, among other things, subject to the terms and conditions thereof, to: (i) vote their beneficially owned securities of the Issuer: (1) in favor of the approval of (i) the issuance of Common Stock to holders of Treeline stock pursuant to the Merger …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-12; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-28 | Casdin Capital, LLC | 24.2% | SCHEDULE 13D/A |
| 2026-01-07 | MAK Capital Fund LP | 5.19% | SCHEDULE 13G |
| 2026-05-15 | Viking Global Investors LP | 15% | SCHEDULE 13G/A |
| 2026-05-15 | MAK Capital Fund LP | 6.7% | SCHEDULE 13G/A |
| 2026-06-09 | Casdin Capital, LLC | 23.9% | SCHEDULE 13D/A |
| 2026-06-12 | Viking Global Investors LP | 15% | SCHEDULE 13D |
| 2026-07-30 | BlackRock, Inc. | 2% | SCHEDULE 13G/A |
| 2026-08-14 | Long Focus Capital Management, LLC | 6% | SCHEDULE 13G |
| 2026-08-14 | Mak Capital One LLC | 7.3% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Standard Biotools Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.